|
|
FDA Safety Changes: Aredia, Avalide, Biaxin, Doryx, Monodox
|
| Link ID |
4925 |
| Title |
FDA Safety Changes: Aredia, Avalide, Biaxin, Doryx, Monodox |
| Url |
http://www.medscape.com/viewarticle/573063?src=rss |
| Description |
The FDA has approved revisions to the safety labeling for pamidronate disodium, irbesartan plus hydrochlorothiazide, clarithromycin, doxycycline hyclate, and doxycycline monohydrate. Medscape Medical News |
| Category |
Articles > Business of Medicine |
| Keywords |
|
| Date |
Apr 17, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Business of Medicine |
| 1. |
Economic Consequences of Early Breast Cancer Treatment Often Severe
|
|
|
With absence from work averaging 7.5 months among women treated for early breast cancer, lost wages are often the most important financial cost of the disease, according to a Canadian study reported in the Journal of the National Cancer Institute for March 5. Reuters Health Information
|
| 4. |
OECD Healthcare Report Shows Big Quality Variation
|
|
|
Death rates from heart attacks have plummeted for people who get to hospitals, but many countries still have trouble treating and preventing chronic diseases, the Organisation for Economic Cooperation and Development reported on Tuesday. Reuters Health Information
|
| 5. |
UK Insurers Extend Freeze on Genetic Testing
|
|
|
British insurers have agreed to extend a freeze on genetic tests to 2014, allowing consumers to continue taking out cover without disclosing the adverse results of tests to predict a predisposition to cancer or heart disease. Reuters Health Information
|
|
|
